Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Innoviva, Inc. (INVA)

12.8   -0.16 (-1.23%) 02-03 16:00
Open: 12.95 Pre. Close: 12.96
High: 13.1 Low: 12.74
Volume: 546,580 Market Cap: 893(M)

Technical analysis

as of: 2023-02-03 3:48:27 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 15.35     One year: 16.11
Support: Support1: 12.1    Support2: 10.06
Resistance: Resistance1: 13.15    Resistance2: 13.8
Pivot: 12.85
Moving Average: MA(5): 12.75     MA(20): 12.98
MA(100): 12.97     MA(250): 14.91
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 43.8     %D(3): 38.9
RSI: RSI(14): 46.9
52-week: High: 20.7  Low: 11.56
Average Vol(K): 3-Month: 597 (K)  10-Days: 531 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INVA ] has closed above bottom band by 47.5%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.04 - 13.09 13.09 - 13.14
Low: 12.6 - 12.66 12.66 - 12.72
Close: 12.86 - 12.96 12.96 - 13.05

Company Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Headline News

Fri, 03 Feb 2023
Great West Life Assurance Co. Can Invests $799000 in Innoviva, Inc ... - MarketBeat

Thu, 02 Feb 2023
Westfield Capital Management Co Increases Position in Innoviva ... - Nasdaq

Thu, 02 Feb 2023
Russia's Role As Arms Exporter Likely Undermined By Its Inva... - MENAFN.COM

Thu, 26 Jan 2023
DekaBank Deutsche Girozentrale Sells 17115 Shares of Innoviva ... - MarketBeat

Mon, 23 Jan 2023
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds - Yahoo Finance

Fri, 20 Jan 2023
Assetmark Inc. Reduces Stake in Innoviva, Inc. (NASDAQ:INVA) - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 70 (M)
Shares Float 58 (M)
% Held by Insiders 0.8 (%)
% Held by Institutions 113.3 (%)
Shares Short 9,440 (K)
Shares Short P.Month 10,240 (K)

Stock Financials

EPS 3.38
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.18
Profit Margin (%) 78.3
Operating Margin (%) 77.8
Return on Assets (ttm) 16.3
Return on Equity (ttm) 58.9
Qtrly Rev. Growth -31.3
Gross Profit (p.s.) 5.6
Sales Per Share 5.34
EBITDA (p.s.) 4.19
Qtrly Earnings Growth 211.1
Operating Cash Flow 291 (M)
Levered Free Cash Flow 210 (M)

Stock Valuations

PE Ratio 3.79
PEG Ratio 0.1
Price to Book value 1.39
Price to Sales 2.39
Price to Cash Flow 3.07

Stock Dividends

Dividend 0.25
Forward Dividend 0
Dividend Yield 1.9%
Dividend Pay Date 2015-09-29
Ex-Dividend Date 2015-09-07
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.